We investigate here the potential of single step production of genetically engineeredmagnetosomes, bacterial biogenic iron-oxide nanoparticles embedded in a lipid vesicle, as a new tailorable magnetic resonance molecular imaging probe. We demonstrate in vitro the specific binding and the significant internalization into U87 cells of magnetosomes decorated with RGD peptide. After injection at the tail vein of glioblastomabearing mice, we evidence in the first 2 h the rapid accumulation of both unlabeled and functionalized magnetosomes inside the tumor by Enhanced Permeability and Retention effects. 24 h after the injection, a specific enhancement of the tumor contrast is observed on MR images only for RGD-labeled magnetosomes. Post mortem acquisition of histological data confirms MRI results with more magnetosomes found into the tumor treated with functionalized magnetosomes. This work establishes the first proof-of-concept of a successful bio-integrated production of molecular imaging probe for MRI.
Introduction
The rise of precision medicine, which aims at tailoring personal medical treatments and therapies but also human well-being monitoring, is highly supported worldwide by public research policies. However, while medical imaging, such as X rays, echography, Positron Emission Tomography (PET) and MRI (Magnetic Resonance Imaging), is daily used to get anatomical and functional information, subcellular and even molecular detection of prognostic and diagnostic physiological markers is striving to reach the patient's bed. In this context, molecular imaging aims at overcoming the lack of specificity and sensitivity of conventional imaging strategies to reveal molecular or cellular phenomenon of medical interest in the less invasive manner. Unraveling such information enables to diagnose diseases at earlier stage and tailor therapeutic strategies to patient's variability.
Molecular imaging requires in many cases the development of specific functionalized contrast agents to reveal molecular or cellular phenomenon with dedicated imaging modality.
Currently, the most advanced modality for this purpose is PET imaging [1] , with a high sensitivity for biomarkers detection, but a low spatial resolution and the use of radioactive compounds as the main drawbacks. Fluorescence imaging is also very promising since it exhibits a very good sensitivity. However, the poor penetration and complex diffusion of photons in living tissues currently restrains its use mainly to intraoperative applications. On the contrary, MRI suffers from poor sensitivity but offers very high spatial resolution [2] , does not rely on radionuclides and can non-invasively provide in-depth information. Its sensitivity can yet be enhanced firstly by increasing the intensity of static magnetic field, secondly by improving the detection sensitivity of radiofrequency coils, and thirdly by optimizing the contrasting part of molecular imaging probes. In particular, iron-oxide nanoparticles are well studied MRI contrast agents [3] . Their contrasting properties can be tuned by changing size and/or shape, or even by doping them with other atoms [3] [4] [5] . In addition, functionalization of the probe surface by suitable ligands can confer selectivity for the targeted biomarker, tissue or organ. Additional probe engineering for drug delivery and other therapeutic effects can convert these vectors into theranostic agents. In this context, functionalization of iron-oxide nanoparticles using different strategies, such as antibodies, aptamers, cell penetrating peptides or drugs, is investigated in a variety of applications, in cancer or inflammation diagnosis for example [4, 5] . Thanks to their metallic core, such agents can also play a key role in cell tracking after transplantation [6] , and can also locally deliver thermal energy for thermoablation therapies [7] . However, since the mineral core of chemically synthesized iron-oxide nanoparticles is not dispersible in biological fluids, various coating strategies have been developed to ensure biocompatibility with additional properties such as vascular retention/clearance, stealthiness, anchoring points for targeting ligand and even encapsulation of active molecules [8] . These engineered molecular probes result from a series of multiple manufacturing steps, each requiring separate optimization with their technical difficulties and cost, thus impeding their wide use.
Recently, studies demonstrated the great interest of biogenic gas nanostructures as potential molecular reporters for ultrasonic imaging [9] , and for labeling and quantifying gene expression by MRI [10] . Likewise, in this study, we explored a new alternative path, based on the use of living organisms, to produce engineered high efficiency molecular imaging probes.
We focused on the potential of magnetosomes, biomineralized iron-oxide nanoparticles naturally coated by a biological membrane and produced by magnetotactic bacteria.
Magnetosomes size and shape are strain dependent [11] and their iron-oxide core presents a very good crystallinity along with a narrow size distribution [12] , and is bigger than the one of conventional chemical iron-oxide nanoparticles [3, 12] . Thus these mono-domain magnetite nanoparticles exhibit permanent magnetization, and are then naturally awarded with high contrasting properties for MRI [13] [14] [15] [16] [17] . Moreover, magnetosomes are naturally biocompatible because of the lipid bilayer surrounding the iron-oxide core [18, 19] , which corroborates their potential as MRI contrast agent [17, [20] [21] [22] . Furthermore, we previously evidenced that magnetosomes easily purified from bacterial cultures can be used as in vivo contrast agent, allowing the visualization of mouse brain angiograms after systemic injection [17] .
Magnetosomes can also be genetically functionalized with peptides or proteins using a translational fusion between the gene coding for an abundant protein specific to the magnetosome membrane, like mamC [23] , and a gene encoding the targeting ligand. The decoration is thus naturally sorted to the membrane leading to a functionalized magnetosome [14, 24] .
Hence, this study establishes the first proof-of-concept of functionalized MRI contrast agent produced in a single step from genetically modified magnetotactic bacteria, in order to perform in vivo MR-based molecular imaging of brain tumor in a mouse model of glioblastoma. Molecular imaging of brain tumor is particularly valuable since it could help performing early diagnosis, as well as monitoring treatment efficiency, and might even be coupled with therapy [4, 25, 26] . To date, brain tumor targeting has been successfully achieved through the EPR (Enhanced Permeability and Retention) effect [27] (a passive targeting due to the leakiness of tumor blood vessels), or by active targeting of angiogenesis molecular biomarkers [25] , such as α ν β 3 integrins overexpressed by tumor cells and in new vascular epithelium [28] , and involved in development of new blood vessels and cell motility [29, 30] . The α ν β 3 integrin can be targeted in vivo using RGD (Arginine, Glycine, Aspartic acid) peptide, which binding efficiency has been demonstrated by several studies [26, 28, 31] .
Thus, we decorated the outer surface of magnetosomes with the RGD peptide by genetically manipulating a Magnetospirillum magneticum AMB-1 strain. To confirm the proper functionalization of magnetosomes, we used the Venus protein as a fluorescent reporter. We characterized in vitro the specific affinity and consecutive internalization of RGD-labeled magnetosomes into U87 glioblastoma cell culturesand confirmed their MRI contrasting properties. We injected RGD-labeled and unlabeled magnetosomes at the tail vein of glioblastoma-bearing mice, and acquired longitudinal series of high spatial resolution MR images. We evidenced the strong accumulation of magnetosomes inside the tumor by EPR effect that persisted long after the complete washout of the nanoparticles from the blood vasculature. Furthermore data analysis revealed a specific enhancement of the tumor contrast on MR images for the RGD-labeled magnetosomes compared to the unlabeled ones. Finally, we cross-validated MRI results with post mortem acquisition of histological data, and provided the first evidence that the affinity and contrast properties of our RGDfunctionalized magnetosomes were suitable for in vivo MR-based molecular imaging of our glioblastoma mouse model.
Materials and methods

Magnetotactic bacteria cultivation and magnetosomes production
Genetically modified Magnetospirillum magneticum AMB-1 [32] cells were anaerobically grown in 7 L bioreactors (Labfors 5, INFORS HT) until late exponential phase. The defined culture medium for anaerobic growth was modified from Murat et al. [33] by increasing the nitrate concentration up to 10 mM. Bacterial cells were harvested by centrifugation and frozen pellets were stored at −20 °C until use. Typically purified magnetosomes suspensions were prepared using the protocol described in Mériaux et al. [17] . 4 g pellets were obtained
by resuspending the cells in 10 mL of Buffer 1 (20 mM HEPES, 1 mM EDTA, 8% glycerol, 0.9% NaCl, pH 7.5). Bacterial cells were disrupted 3 times with a French press (1200 psi). Magnetosomes were magnetically purified with a MACSiMAG™ separator (Miltenyi Biotec).
The magnetic nanoparticles were then washed and magnetically purified 10 times in 10 mL of Table 1 ) from a local plasmid containing the venus gene. After double enzymatic digestion with BamHI and SacI, the PCR products were then cloned at the corresponding sites into the previously digested plasmid. In the pMamC-VenusRGD vector, the 3′ extremity of the mamc::venusRGD chimeric genecodes for an 11 aminoacids peptide (ACDCRGDCFCG) bearing the RGD motif. Magnetospirillum magneticum AMB-1 wild-type strain was transformed by conjugation as described by Ginet et al. [24] . 
Transmission electron microscopy
For TEM imaging, 10 μL deposits of diluted magnetosomes suspension were allowed to sediment for 1 min onto 200 mesh copper grids covered by a formvar-carbon film. After removal of the liquid with Kimwipe paper, digital electron micrographs were recorded with a Tecnai™ G2 BioTWIN transmission electron microscope (FEI Company) at 100 kV acceleration voltage.
Confocal microscopy
Confocal microscopy images presented in Fig. 1a were collected on a Zeiss LSM880 confocal microscope equipped with an Airyscan detector (Carl Zeiss) using a Plan- 
Fig. 2. In vitro study of AMB1 VRGD affinity to U87 cells. A/ ×40 magnification fluorescence and bright-field images of U87 cells, after 3h30 of incubation with AMB1 V (control) or AMB1 VRGD (2 mg Fe /L). A-a,c/ Merged fluorescence images show cell nuclei (DAPI staining in blue), cell membranes (Texas Red, Wheat Germ Agglutinin staining in orange), V or VRGD proteins (YFP in green). A-b,d/ Bright-field images show clusters of ironoxide crystals. B/ Quantification of [Venus+/WGA+] pixels is performed on mosaic images, obtained after the same incubation protocol (see Supplementary Fig. S2). Count of [Venus+/WGA+] pixels is normalized by the number of detected cell nuclei, and plotted for AMB1 V and AMB1 VRGD incubation conditions.
Fig. 3. In vitro study of AMB1 VRGD internalization inside U87 cells. ×63 magnification fluorescence and bright-field images of U87 cells, after 24 h of incubation with AMB1 VRGD (250 μg Fe /L). a/ Merged fluorescence image acquired before detergent treatment shows cell nuclei (DAPI staining in blue) and magnetosomes localized only outside cells (anti-AMB1 staining revealed in red). b/ Merged fluorescence image acquired after detergent treatment shows cell nuclei (DAPI staining in blue) and all magnetosomes (anti-AMB1 staining revealed in green). c/ Bright-field image acquired after detergent treatment shows clusters of ironoxide crystals. d/ Overlay of previous fluorescence and bright-field images (a,b,c) reveals in green magnetosomes localized only inside cells.
/ ×20 magnification mosaic fluorescence images acquired after immunostainings of histological mouse brain slices (20 μm thickness), showing vessels (anti-CD31 staining revealed in green) and magnetosomes (anti-AMB1 staining revealed in red). Mice were injected with AMB1 V (upper panel) or AMB1 VRGD (lower panel) magnetosomes. b/ Upper panel: ×63 fluorescence image of an AMB1 VRGD-injected mouse brain slice showing magnetosomes within (green arrows) or outside (red arrow) vessels. DAPI-stained cell nuclei appear in blue. Lower panel: ×63 confocal Z-section (0.38 μm) with orthogonal views of the same mouse brain slice, confirming the co-localization of AMB1 VRGD magnetosomes (revealed in red) within vessels (revealed in green). c/ Quantification of anti-AMB1 positive pixels (magnetosomes) co-localized with anti-CD31 positive pixels (vessels) inside brain tumors (n = 3 mice analyzed for AMB1 VRGD group and n = 2 mice analyzed for AMV1 V group).
Production of rabbit polyclonal antibodies against AMB1 magnetosomes
450 μg (215 μL) of magnetosomes (AMB-1) were mixed with an equal volume of complete
Freund's adjuvant (Sigma Aldrich) and were then injected subcutaneously into two 3 monthold New Zealand White rabbits (Charles River). The rabbits were fed ad libitum with a regular commercial diet (Kliba Nafag). The following injections were performed on days 28, 58 and 91 with incomplete Freund's adjuvant. 14 days after each boost, blood samples were collected from the rabbits and the antibodies against magnetosomes were titrated by ELISA test. (Abcam). Then, α ν β 3 integrins were stained with a mouse anti-α ν β 3 antibody revealed in orange (MAB1976H-PE, Millipore, 1/100 dilution, 1 h incubation), and cell nuclei were revealed in blue with DAPI.
In vitro U87 cells culture
In vitro measurement of magnetosomes transverse relaxivity r 2
Transverse relaxivity r 2 was measured twice for each type of magnetosomes, AMB1 V and AMB1 VRGD. One measurement consisted in building a phantom containing 6 tubes filled with magnetosomes at different iron concentrations suspended in 0.3% w/w agar. MRI experiments were launched around 21 days after implantation, when the tumor diameters were around 3 mm.
In vivo MR-based molecular imaging studies
For both short-term (0-100 min after injection) and long-term (0-24 h after injection) studies, MRI acquisitions were performed on an 11.7 T MRI BioSpec preclinical scanner equipped with a radiofrequency cryogenic coil dedicated to mouse brain (Bruker). Mice were anesthetized using an air/O 2 mixture (50:50) and isoflurane(3%), before being positioned into dedicated cradle. Respiration rate was continuously monitored and body temperature was kept close to 37 °C thanks to a warm water circulation system. After acquiring baseline scans, the cradle was removed out of the magnet tunnel while keeping the mouse positioned, and injection of 200 μmol of iron per kg of body weight of magnetosomes suspension (54 mM [Fe] ) was performed at the mouse caudal vein with a 29 G syringe. The cradle was afterward quickly inserted back into the tunnel for acquiring post-injection MRI scans.
To reveal the T 2 * negative contrast induced by the injection of magnetosomes, a T 2 *-weighted FLASH (Fast Low Angle SHot) sequence was used with the following parameters: Right after the last MRI session, mice were euthanized with an overdose of Xylazine/Ketamine, intracardiacally perfused with NaCl 0.9% to remove blood and then fixed with PFA 4%. Brains were extracted, post-fixed 2 h in PFA 4%, soaked in sucrose solutions (15% followed by 30%), frozen by immersion in −30 °C isopentane to be finally stored at −80 °C for histological analysis.
In vivo MR images processing
All in vivo MRI data were processed with homemade Matlab routines. For the shortterm study, brain tumor volumes were manually segmented on reconstructed FLASH images.
To follow the contrast enhancement in the tumor area, the normalized R 2 * (= 1/T 2 *) enhancement was estimated as follows [34] : ΔR2 * t=1TElogmeanStPRESt, S being the FLASH signal inside the tumor. This ΔR 2 * parameter was computed for the different time points t after magnetosomes injection, and the mean and standard deviation of ΔR 2 * for both groups of mice were plotted versus time (Fig. 4b) .
For the long-term study, brain tumor volumes were manually segmented on T 2 * parametric maps reconstructed from MGE images. To follow the contrast enhancement in the tumor area, the normalized decrease of T 2 * was estimated for the different time points t after magnetosomes injection as follows: ΔT2 * (t)=(T2 * PRE−T2 * POST(t)T2 * PRE). To compare the tumor targeting properties of injected magnetosomes, the means of ΔT * 2 estimated for all tumor voxels were pooled together for both groups of mice at 30 min and 24 h post-injection (Fig. 5b) . A non-parametric Wilcoxon signed-rank test was ran to evaluate the statistical significance of the 30 min versus 24 h post-injection differences, as well as the AMB1 V versus AMB1 VRGD differences.
Post mortem histological analysis
Brain samples were cut into 20 μm thickness slices with a cryomicrotome, and positioned on glass slides. Immunohistochemical stainings were performed to stain i) vessels with a rat anti-CD31 antibody (MCA2388, AbD Serotec, 1/50 dilution, 1 h incubation) revealed in green with a donkey anti-rat Alexa Fluor ® 488 (Abcam), ii)α ν β 3 integrins with a mouse anti-α ν β 3 antibody revealed in orange (MAB1976H-PE, Millipore, 1/100 dilution, 1 h incubation), and iii) AMB1 magnetosomes with the rabbit anti-AMB1 antibody specifically produced for this study (1/5000 dilution, 1 h incubation), revealed in red with a donkey anti-rabbit Alexa at ×20 magnification for mosaic images covering the whole tumor area, and at ×63 magnification for single field-of-view focusing on structures of interest inside the tumor.
Fluorescence images processing
All fluorescence microscopy data were processed using homemade Matlab routines. After four times downsampling of native images, quantification of in vitrodata (Fig. 2B ) was done by thresholding orange (WGA, cells membrane) and green (Venus, magnetosomes) channels. The image of thresholded orange channel was slightly dilated to smooth borders and fill potential holes. Both masked images were then clusterized: if a green cluster overlapped an orange one, it was considered as co-localized (Venus+/WGA+), otherwise it was considered as isolated (Venus+/WGA-).
A similar procedure was applied to analyze post mortem histological data on whole tumor (Fig. 6c) . One coronal slice containing a full section of the tumor and crossing its center was analyzed per mice (n = 3 animals in AMB1 VRGD group and n = 2 in AMB1 V group). After a manual segmentation of the tumor zone on the orange channel (α ν β 3 integrins), the green (anti-CD31, vessels) and red (anti-AMB1, magnetosomes) channels were thresholded. The image of thresholded green channel was slightly dilated, and then both masked images were clusterized: a red cluster detected in the tumor was considered inside a vessel when an overlap with a green cluster occurred (anti-AMB1+/anti-CD31+).
Results
We established in a previous study the suitability of wild-type magnetosomes to be used as highly efficient T 2 -shortening agents for in vivo brain imaging in mice with MRI [17] . The following Results section describes the preparation of RGD-functionalized magnetosomes suspensions readily injectable into the mouse blood circulation, the assessment of the targeting strategy on U87 tumor cell cultures and finally its validation in vivo on glioblastomabearing mice assisted by high-field 11.7 T MRI.
Injectable suspensions of genetically modified magnetosomes
The magnetotactic M. magneticum AMB-1 strain was genetically modified to express at the magnetosome surface a RGD peptide (known to target α ν β 3 integrin receptors) attached to the Venus variant of the Green Fluorescent Protein (GFP). To do so, we designed a transcriptional fusion between the DNA sequences encoding Venus (AMB1 V strain) or Venus-RGD proteins (AMB1 VRGD strain) with the mamCgene coding for an abundant protein of the magnetosome membrane. The Venus protein served as a fluorescent marker during the magnetosomes purification, as a spacer for an efficient display of the RGD peptide at the magnetosome surface and as a fluorescent reporter for fluorescence microscopy. In live bacteria, one could observe in confocal microscopy a series of Venus fluorescence foci aligned within the cell, reminiscent of the magnetosomes chain organization (Fig. 1a ), hinting at a proper functionalization of the magnetosome membranes with the Venus and Venus-RGD proteins. Magnetosomes were then magnetically extracted from crude cellular lysates after mechanical disruption by a French press, and after several washing steps, the purified magnetosomes were conditioned in readily injectable doses at the final iron concentration of 54 mM. The nanoparticle size distribution was computed from TEM images (Fig. 1b) , resulting in a mean typical length value of 45 nm, and the persistence of the functionalization was verified throughout the production process with fluorescence spectroscopy and Western blot analysis( Fig. 1c and d 
Specific binding of RGD magnetosomes to U87 tumor cells
As a prerequisite to the injection to alive glioblastoma-bearing mice, we assessed the affinity of the RGD magnetosomes for U87 cells issued from human primary glioblastoma, known to overexpress α ν β 3 integrins [35, 36] . Thanks to the Venus fluorophore decorating the membrane surface for both control (AMB1 V) and RGD (AMB1 VRGD) magnetosomes, the fate of these nanoparticles could be easily followed by fluorescence microscopy. U87 cells were incubated during 3h30 with the magnetosomes at a final iron concentration of 36 μM.
Cell membranes and nuclei were then stained respectively with Wheat Germ
Agglutinin (WGA) and DAPI, before cells observation by fluorescence and in bright-field microscopy. In the representative fluorescence images shown in Fig. 2A , magnetosomes (Venus fluorescence) appear in green, cell membranes in orange and nuclei in blue, whereas iron-oxide cores are revealed as dark spots in bright-field images. Many bright Venus spots seemed mostly co-localized with U87 cells when they were previously incubated with AMB1
VRGD magnetosomes ( Fig. 2A, panel c) , while very few Venus fluorescence foci could be seen with the control AMB1 V magnetosomes ( Fig. 2A, panel a) . In both cases, Venus fluorescence overlapped with the iron-oxide core observed in bright-field images ( Fig 
RGD magnetosomes internalization into U87 cells
Active internalization of RGD-functionalized nanoparticles upon binding thanks to integrin recycling [37, 38] is known to efficiently load the targeted cells with nanoparticles. We thus investigated whether magnetosomes can be internalized after binding to U87 cells thanks to RGD peptide. The apparent co-localization observed in the fluorescence images between cell membranes and magnetosomes (Fig. 2) could result either from nanoparticles bound at the cell surface or internalized into the cells. Since we could not distinguish between the two situations with Venus fluorescence alone, we used a polyclonal antibody raised against the magnetosome membrane to discriminate magnetosomes sitting outside from those sitting inside U87 cells. Furthermore, the incubation time was lengthened up to 24 h to insure enough internalization if any, and the magnetosomes dose was diminished to 4.5 μM to avoid fluorescence saturation. Briefly, after 24 h of incubation of either the control (AMB1 V, Supplementary Fig. S3 ) or RGD-functionalized (AMB1 VRGD, Fig. 3 ) magnetosomes with intact U87 cells, followed by washes and cell fixation, magnetosomes bound at the outer surface of the U87 cells were revealed by immunohistochemical staining (anti-AMB1 out , red channel in Fig. 3a) . Cells membranes were subsequently permeabilized by a mild detergent treatment allowing the antibodies to diffuse into the cytosol, thus resulting in the immunohistochemical detection of the entire magnetosomes population, i.e. those bound at the surface and those internalized (anti-AMB1 all , green channel in Fig. 3b ). The internalized fraction was simply deduced by signal difference obtained before and after detergent treatment, and appeared in green when channels were merged while the outside bounded fraction appeared in yellow (Fig. 3d) . For the unlabeled magnetosomes, we observed that the permeabilization of the plasma membranes did not bring out any more fluorescence but the yellow one ( Supplementary Fig. S3 ), meaning that the entire fluorescence sits outside of the cells, because of unspecific attachment to U87 cells or to the bottom of glass plates. This was not the case with the RGD magnetosomes, where the permeabilization of the plasma membranes enabled the detection of many discrete green fluorescent dots situated within the cell boundaries in addition to the yellow ones (Fig. 3d) .
The results presented in Fig. 3 suggest an active transport of the RGD magnetosomes across the cell membrane upon binding to the α ν β 3 integrins, which is in accordance with observations previously made for other, non-biogenic, RGD-functionalized nanoparticles [31] . Together, these in cellulo data indicate that the RGD-functionalized magnetosomes target the α ν β 3 integrin receptorsoverexpressed by U87 cells issued from human primary glioblastoma and accumulate within the cytosol, therefore justifying further in vivo investigations in glioblastoma-bearing mice with high-field MRI.
In vivo demonstration of RGD magnetosomes affinity and retention in brain tumor
Firstly, in vivo MRI experiments were performed by injecting magnetosomes (control or RGD) to a mouse model of glioblastoma, in order to validate that both magnetosomes could equally circulate in blood stream for a couple of hours, especially in the brain and in the tumor. AMB1 V can be used as a control for AMB1 VRGD in in vivo studies only if they produce similar MRI contrast, meaning that a comparable amount of magnetosomes reaches tumor vessels. This has been tackled by following the contrast in the mouse brain with the highest imaging rate and as long as possible right after magnetosomes intravenous injection. This protocol was designed to follow during 100 min the MRI contrast enhancementinduced in brain tumor after RGD-functionalized or control magnetosomes injection to tail vein of glioblastoma-bearing mice. A T 2 *-weighted FLASH imaging strategy has been chosen to ensure an imaging rate of one image every 5 min, still providing very high spatial resolution (75 μm isotropic). FLASH images acquired before and 15 min after injection revealed that both types of magnetosomes injections led to a very rapid and abundant increase of the number of detected hypo-intense voxels in the tumor area (white arrows in Fig. 4a ). Furthermore, this increase of hypo-intense voxels number seemed to maintain in time until 100 min. Observation of FLASH images was assessed with a semi-quantitative measurements of MRI signal loss (ΔR 2 * parameter), by normalizing the signal in the tumor by its value before injection. ΔR 2 * values showed a sharp increase right after injection and then reached a similar plateau in each group of mice (control and RGD-functionalized magnetosomes, grey circles and black squares in Fig. 4b respectively), revealing that in the time frame of 100 min, both injected magnetosomes steadily circulated in tumor vasculature.
These observations settle in vivo the high MRI contrasting properties of the magnetosomes suspensions prepared for this study, in line with the in vitrodemonstration by the transverse relaxivity measurements (Fig. 1e) . Magnetosomes steadily circulating in in vivo physiological condition during at least 100 min means that their blood half-lives are longer than 2 h. Thus, both magnetosomes present good bio-compatibility properties and similar in vivo contrasting properties, which validates the use of AMB1 V as a control for AMB1 VRGD for the in vivo study of magnetosomes binding. (Fig. 5b) . A high and similar uptake was observed in both groups 30 min after injection, which is in agreement with the previous experiment and corroborates that both magnetosomes are comparable blood pool agents, i.e. the RGD functionalization does not alter their blood circulation properties.
Nevertheless, a significant difference in uptake between the two treatments was observed 
Discussion
We successfully designed and produced genetically modified magnetosomes from wildtype AMB1 strain of magnetotactic bacteria, integrating a RGD peptide in order to target α ν β 3 integrin receptors, combined with a fluorescent protein marker (Venus) successfully used to follow the particles in in vitro studies. We evidenced that the MRI contrasting properties at 11.7 T measured for unlabeled and functionalized magnetosomes (r 2 values around 550 mM
) are comparable and in good agreement with previous measurements obtained for other magnetotactic bacteria strains and at different intensities of magnetic field [17, 20, 22] . These high r 2 values compared to those of many chemical nanoparticles [3] lead to high MRI sensitivity, which makes magnetosomes very good candidates for MR-based molecular imaging applications.
We demonstrated in vitro that RGD peptides, bioproduced at magnetosomes surface by magnetotactic bacteria, exhibit sufficient affinity to specifically bind to their target, the α ν β 3 integrins overexpressed at U87 tumor cells membrane. We revealed that this effective binding can lead to magnetosomes internalization inside tumor cells, thanks to a specific experimental protocol set up to differentiate magnetosomes standing outside or inside U87 cell membrane. The results confirmed that the interactions between our functionalized probe and its target correspond to a highly dynamic process, from the binding up to the internalization [37] . Indeed, α ν β 3 integrins are constantly recycled from cell membrane to intracellular vesicles, which are then recycled back to membrane with a half-life around 10 min [29] . Therefore, RGD-functionalized magnetosomes can bind to tumor cells membrane and afterward being internalized, which implies that one should take great care of both dosage and injection timing when optimizing the tumor targeting efficiency.
Molecular imaging of U87 brain tumor has been carried out in vivo on mice at two different time scales after magnetosomes injection. This enabled to tackle in a first step the general behavior of AMB1 magnetosomes in vivo, in order to assess that both AMB1 V and AMB1
VRGD are efficient MRI contrast agents and present comparable properties. Indeed, in the first hundred minutes post-injection, both probes show a high efficiency in enhancing MRI contrast between tumor and healthy brain, and a similar bio-availability in the tumor area.
Time frame of imaging compared to administration strategy of molecular imaging probe is actually a key parameter. Non-functionalized iron-oxide nanoparticles are expected to be blood pool agents at the hour scale, and are afterward suitable for reticuloendothelial system (macrophages, liver, spleen, lymph node, among others) imaging since they are eliminated from the blood stream by this path [2, 3] . Inside brain tumors, the increased permeabilization of blood-tumor barrier (EPR effect) allows a passive targeting of tumor parenchyma by nanoparticles [27] . This passive targeting through EPR effect is highlighted by the tumor area presenting darker signal than healthy brain until 100 min after magnetosomes injection.
Furthermore, this passive targeting can also be appreciated as the remaining tumor uptake of AMB1 V magnetosomes 24 h post-injection. Regarding RGD-functionalized magnetosomes, their active targeting properties combined to the EPR effect lead to a significantly higher retention inside tumor parenchyma compared to control magnetosomes, as highlighted by mortem histological data that confirm a higher retention of magnetosomes in tumors of AMB1 VRGD treated mice compared to controls. The RGD peptide localized at magnetosome membrane can specifically target tumor biomarkers, such as α ν β 3 integrins overexpressed by tumor neo-angiogenic vessels, leading AMB1 VRGD to be held into tumor area.
In these in vitro and in vivo studies, magnetosomes have been incubated with mammalian cells and injected to mice, and it is noteworthy that no specific adverse effect was observed (good cell viability, good general condition of animals after injection up to 24 h). Our observations were consistent with recent investigations on the biocompatibility of purified magnetosomes: several in-depth studies, performed on either rats or mice, showed no toxicity of the magnetosomes used at this range of low concentrations (200 μmol of iron per kg of body weight of magnetosomes suspension), and revealed that magnetosomes appeared to be fully degraded in vivo after 28 days by cell lysosomes [19, [39] [40] [41] [42] [43] [44] .
Nevertheless, further biodistribution and toxicity studies need to be carried out to unravel the long term fate of our functionalized magnetosomes.
Our in vivo MRI results demonstrated the feasibility of using a fully biogenic molecular imaging probe to target brain tumor in a mouse model of human glioblastoma. Nevertheless, some issues regarding the optimization of both specificity and sensitivity of this targeting remain to tackle. Firstly, regarding the chosen application, the next step could be to study the influence of both dose and imaging timing on detection of iron accumulation inside the tumor.
For example, it would be very interesting to investigate different injection procedures: in this study, we chosen a standard intravenous bolus injection, but trying continuous infusion of smaller magnetosomes doses on a longer time frame might increase the tumor uptake, since it is expected to maximize the probe exposure to its target. Moreover, to further enhance targeting properties of functionalized magnetosomes, replacing linear RGD peptide for a more affine form, like the cyclic penetrating RGD for example [28] , could help to increase probe specificity. Finally, theranostic applications could be considered by setting new hyperthermia protocols. Hyperthermia is a well-known and extensively investigated technique for thermotherapy of tumors [7] , and several studies have already demonstrated the therapeutic effect induced by magnetic hyperthermia applied to magnetosomes directly injected inside the tumor [45, 46] . The efficiency of tumor treatment by hyperthermia could be improved thanks to the active targeting of neo-angiogenic vessels localized inside tumor obtained with functionalized magnetosomes. Furthermore, it also opens the way to less invasive magnetic hyperthermia protocols, by replacing intra-tumoral injection with intravenous one.
Conclusion
In summary, this work embodies the first achievement in producing, under biological processes, a specific and sensitive molecular imaging probe for MRI. Knowing that magnetosomes size and shape are strongly strain-dependent [12] , it is then possible to further tune MRI contrasting properties and tailor targeting affinity by changing bacteria strain and strategy for genetic modifications. Magnetotactic bacteria would therefore become integrated nano-factories providing customized functionalized contrast agents for a wide range of diagnostic and theranostic applications. This proof-of-concept not only paves the way for further improvements regarding our application, but also strengthens the potential interest of developing biogenic probes for in vivo molecular imaging applications. All authors contributed to manuscript edition.
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